PDF DatasheetHuman Anti-ETS1 Antibody Product Attributes
ETS1 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-ETS1 antibody staining is expected to be primarily localized to the nucleoplasm. There is variability in either the signal strength or the localization of signal in nucleoplasm from cell to cell.
Observed Antibody Staining Data By Tissue Type:
Variations in ETS1 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in germinal center cells in the tonsil, hematopoietic cells in the bone marrow, lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. More moderate antibody staining intensity was present in germinal center cells in the tonsil, hematopoietic cells in the bone marrow, lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. Low, but measureable presence of ETS1 could be seen in. We were unable to detect ETS1 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of ETS1 expression as measured by anti-ETS1 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | ++ | + | – | – | – | – | – | – | – | – | – |
| ETS1 Variability | + | + | + | + | + | + | + | + | + | ++ | ++ | + | + | + | + | + | + | + | + | + |
| ETS1 General Information | |
|---|---|
| Alternate Names | |
| Protein C-ets-1, ETS1 | |
| Molecular Weight | |
| 54kDa | |
| Chromosomal Location | |
| 11q23.3 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | ETS1 |
| Entrez Gene ID | 2113 |
| Ensemble Gene ID | ENSG00000134954 |
| RefSeq Protein Accession(s) | XP_011540954, XP_016872805, NP_001317380, XP_011540952, XP_016872804, NP_005229, XP_011540953, XP_011540951, XP_016872806, NP_001137292, XP_016872803, NP_001155894 |
| RefSeq mRNA Accession(s) | XM_017017314, NM_001162422, XM_011542650, NM_005238, XM_011542652, XM_017017317, XM_017017315 NM_001143820, XM_011542649, XM_017017316, XM_011542651, NM_001330451 |
| RefSeq Genomic Accession(s) | NG_029555, NC_000011, NC_018922 |
| UniProt ID(s) | P14921, B4DW78, A8K725 |
| UniGene ID(s) | P14921, B4DW78, A8K725 |
| HGNC ID(s) | 3488 |
| Cosmic ID(s) | ETS1 |
| KEGG Gene ID(s) | hsa:2113 |
| PharmGKB ID(s) | PA27902 |
| General Description of ETS1. | |
| ETS1 proto-oncogene is an important transcription factor that plays a role in cell proliferation and differentiation. ETS1 is related to the growth of carcinoma cells by its regulation of the transcription of matrix metalloproteinases and urokinase-type plasminogen activator. The processes of tumor invasion and metastasis depend on the increased proteolytic activity of the invading tumor cells that may involve matrix metalloproteinases, cathepsins B and D and plasminogen activator in the metastatic cascade. ETS1 is preferentially expressed in lymphoid cells, where it is essential for the maintenance of the normal pool of resting T and B cells. ETS1 expression level and distribution are differentially controlled in resting, activated and apoptotic lymphocytes. | |
There are no reviews yet.